Piper Sandler raised the firm’s price target on Fulgent Genetics (FLGT) to $30 from $21 and keeps a Neutral rating on the shares. The firm cites the company’s quarterly results for the price target change.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT: